BRIEF published on 05/23/2024 at 11:40, 1 year ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
BRIEF published on 05/23/2024 at 11:40, 1 year ago Franchissement de seuils pour GENSIGHT BIOLOGICS S.A. Actions Franchissement De Seuils Bons De Souscription GenSight Biologics Armistice Capital
PRESS RELEASE published on 05/23/2024 at 11:35, 1 year ago Franchissement de seuils Déclaration de franchissement de seuils par Armistice Capital, LLC concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils Armistice Capital LLC GENSIGHT BIOLOGICS SA Déclaration Régularisation
BRIEF published on 05/07/2024 at 19:34, 1 year ago GenSight Biologics annonce la mise à disposition d'un prospectus pour la cotation de nouvelles actions sur Euronext Paris Euronext Paris Augmentation De Capital Thérapie Génique Prospectus Produits Biologiques GenSight
BRIEF published on 05/07/2024 at 19:34, 1 year ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
PRESS RELEASE published on 05/07/2024 at 19:29, 1 year ago Modalités de mise à disposition de prospectus GenSight Biologics annonce la mise à disposition d'un prospectus pour l'admission d'actions nouvelles sur Euronext Paris. La société spécialisée dans les thérapies géniques pour les maladies neurodégénératives informe sur le processus Euronext Paris Prospectus GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
PRESS RELEASE published on 05/07/2024 at 19:29, 1 year ago Terms of availability of prospectuses GenSight Biologics announces availability of listing prospectus for new shares on Euronext Paris. The prospectus approved by AMF includes universal registration document, securities note, and summary Euronext Paris New Shares AMF Approval GenSight Biologics Listing Prospectus
Published on 05/31/2025 at 06:16, 16 hours 25 minutes ago Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE
Published on 05/31/2025 at 03:30, 19 hours 11 minutes ago Avant Brands Inc. Announces Voting Results From 2025 Annual General Meeting of Shareholders
Published on 05/31/2025 at 01:45, 20 hours 56 minutes ago GLG Life Tech Corporation Reports 2025 First Quarter Financial Results
Published on 05/30/2025 at 23:10, 23 hours 31 minutes ago CORRECTION: Nextech3D.ai Migrates MAP Dynamics to AWS, Enabling Scalable AI Architecture and Accelerated Deployment
Published on 05/30/2025 at 23:00, 23 hours 41 minutes ago Battery X Metals Achieves Full Capacity Recovery on a Real-World Imbalanced Battery from the #2 Out-of-Warranty Electric Vehicle Model in the United States in Preliminary Trial
Published on 05/31/2025 at 21:00, 1 hour 41 minutes ago Leclanché annonce le dépôt d'une demande de prolongation du délai de publication du rapport annuel 2024 et la suspension temporaire de la cotation de ses actions nominatives à la SIX Swiss Exchange
Published on 05/31/2025 at 21:00, 1 hour 41 minutes ago Leclanché SA: Leclanché announces filing of request to extend the publication deadline for the 2024 Annual Report and the temporary suspension of trading of its registered shares on SIX Swiss Exchange
Published on 05/31/2025 at 18:37, 4 hours 4 minutes ago Meyer Burger files for insolvency for German subsidiaries
Published on 05/31/2025 at 14:50, 7 hours 50 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 05/31/2025 at 14:46, 7 hours 55 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 05/28/2025 at 23:00, 2 days 23 hours ago Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 2 days 23 hours ago Engagements collectifs de conservation de titres de la société
